AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Nifenazone is effective in providing relief from mild to moderate pain associated with various conditions, including musculoskeletal pain, joint pain, dental pain, headaches, menstrual cramps, and postoperative pain. It works by inhibiting the synthesis of prostaglandins, which are substances involved in the transmission of pain signals.
Anti-inflammatory Effects: Similar to other NSAIDs, nifenazone exerts anti-inflammatory effects by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking the production of prostaglandins, nifenazone helps reduce inflammation, swelling, and redness at the site of tissue injury or inflammation.
Fever Reduction: Nifenazone possesses antipyretic properties, meaning it can help lower fever by acting on the hypothalamus in the brain, which regulates body temperature. By inhibiting prostaglandin synthesis in the hypothalamus, nifenazone helps bring down elevated body temperature associated with infections or inflammatory conditions.
Musculoskeletal Disorders: Nifenazone is commonly used to manage musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, tendonitis, and bursitis. By alleviating pain and inflammation in the affected joints, muscles, and connective tissues, nifenazone helps improve mobility and quality of life in individuals with these conditions.
Other Conditions: Nifenazone may also be used to relieve pain and inflammation associated with conditions such as sciatica, neuralgia, sprains, strains, sports injuries, and minor traumas. It is often prescribed as part of a comprehensive treatment plan that may include rest, physical therapy, and other pain management strategies.
Side Effects: While nifenazone can be effective for pain relief and inflammation, it may also cause side effects, particularly when used at high doses or for prolonged periods. Common side effects of nifenazone may include gastrointestinal disturbances such as stomach pain, indigestion, nausea, vomiting, diarrhea, and gastrointestinal ulcers or bleeding. In rare cases, nifenazone may cause allergic reactions, skin rash, dizziness, headache, and liver or kidney problems.
Precautions: Before using nifenazone, individuals should inform their healthcare providers about any preexisting medical conditions, allergies, or medications they are taking, as well as their pregnancy or breastfeeding status. Nifenazone should be used with caution in individuals with a history of gastrointestinal ulcers or bleeding, cardiovascular disease, kidney dysfunction, or liver impairment.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.4 | 0.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.7 | |
| Allergies | 1.1 | 1.1 | |
| Allergy to milk products | 0.9 | 0.5 | 0.8 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 1 | 1.3 | -0.3 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.7 | 0.14 |
| Ankylosing spondylitis | 1.8 | 0.2 | 8 |
| Anorexia Nervosa | 0.1 | 0.3 | -2 |
| Antiphospholipid syndrome (APS) | 0.8 | 0.8 | |
| Asthma | 0.3 | -0.3 | |
| Atherosclerosis | 0 | 0.1 | 0 |
| Atrial fibrillation | 0.7 | 0.7 | 0 |
| Autism | 1.4 | 1.5 | -0.07 |
| Barrett esophagus cancer | 0.3 | 0.1 | 2 |
| benign prostatic hyperplasia | 0.4 | 0.4 | |
| Bipolar Disorder | 0.7 | 0.3 | 1.33 |
| Brain Trauma | 0.3 | -0.3 | |
| Carcinoma | 0.8 | 0.4 | 1 |
| Celiac Disease | 1.3 | 0.6 | 1.17 |
| Cerebral Palsy | 0.3 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 1 | 1.2 | -0.2 |
| Chronic Kidney Disease | 0.9 | 0.1 | 8 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.1 | 5 |
| Chronic Urticaria (Hives) | 1.4 | 0.4 | 2.5 |
| Coagulation / Micro clot triggering bacteria | 1.3 | 0.2 | 5.5 |
| Colorectal Cancer | 2.2 | 2.2 | |
| Constipation | 0.5 | 0.1 | 4 |
| Coronary artery disease | 0.2 | -0.2 | |
| COVID-19 | 2.4 | 1.1 | 1.18 |
| Crohn's Disease | 2.3 | 0.8 | 1.87 |
| cystic fibrosis | 1.1 | 0.3 | 2.67 |
| deep vein thrombosis | 1.1 | 0.2 | 4.5 |
| Depression | 2.5 | 1.9 | 0.32 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.6 | 0.7 | -0.17 |
| Endometriosis | 1.5 | 0.3 | 4 |
| Eosinophilic Esophagitis | 0 | 0.2 | 0 |
| Epilepsy | 1 | 0.6 | 0.67 |
| Fibromyalgia | 0.8 | 0.3 | 1.67 |
| Functional constipation / chronic idiopathic constipation | 1.7 | 0.9 | 0.89 |
| gallstone disease (gsd) | 0.8 | 0.1 | 7 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.1 | 5 |
| Generalized anxiety disorder | 1.1 | 0.2 | 4.5 |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.3 | 0.1 | 2 |
| Halitosis | 0.4 | 0.1 | 3 |
| Hashimoto's thyroiditis | 0.5 | 0.2 | 1.5 |
| Hidradenitis Suppurativa | 0.1 | 0.2 | -1 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | 0.1 | 9 |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.4 | 0.3 | 0.33 |
| hypertension (High Blood Pressure | 0.8 | 1 | -0.25 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 2.2 | 0.9 | 1.44 |
| Insomnia | 0.3 | 0.3 | 0 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1.6 | 0.8 | 1 |
| Liver Cirrhosis | 1.2 | 0.6 | 1 |
| Long COVID | 1.3 | 0.5 | 1.6 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.4 | 0 | 0 |
| ME/CFS with IBS | 0.1 | 0.2 | -1 |
| ME/CFS without IBS | 0.2 | 0.6 | -2 |
| Metabolic Syndrome | 2 | 1.3 | 0.54 |
| Mood Disorders | 3 | 1.9 | 0.58 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 0.5 | 1.2 | -1.4 |
| Multiple system atrophy (MSA) | 0.2 | 0.2 | |
| Neuropathy (all types) | 0.1 | 0.4 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.2 | 1.5 |
| Obesity | 1.5 | 1.1 | 0.36 |
| obsessive-compulsive disorder | 2.2 | 0.4 | 4.5 |
| Osteoarthritis | 0.9 | 0.9 | |
| Osteoporosis | 0.8 | 0.2 | 3 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 1 | 1.2 | -0.2 |
| Polycystic ovary syndrome | 0.7 | 0.1 | 6 |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| primary biliary cholangitis | 0 | 0.1 | 0 |
| Psoriasis | 1.5 | 0.7 | 1.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1 | 0.9 | 0.11 |
| Rosacea | 0.2 | 0.1 | 1 |
| Schizophrenia | 0.9 | 0.1 | 8 |
| Sjögren syndrome | 1.3 | 0.4 | 2.25 |
| Sleep Apnea | 0 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 1.2 | 0.3 | 3 |
| Systemic Lupus Erythematosus | 1.4 | 0.1 | 13 |
| Tic Disorder | 0 | 0 | 0 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 1.1 | 0.2 | 4.5 |
| Type 2 Diabetes | 2 | 1.8 | 0.11 |
| Ulcerative colitis | 1.6 | 0.5 | 2.2 |
| Unhealthy Ageing | 1.2 | 0.1 | 11 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.